Table 1.
Quality of MD reporting according to current reporting guidance
| Reporting category | MD reporting criterion | Proportion of trials reporting criteria |
|---|---|---|
| Proportion of MD | Account for all participants who enter the studya | 69% (75/108) |
| Report number of participants not included in the primary outcome analysisa | 94% (101/108) | |
| Report number of participants with MD in each arm in the primary outcome analysisab | 87% (85/98)b | |
| Report amount of item-levelc MD in the primary outcome analysis | 10% (5/50)d | |
| Report MD trend over time for primary outcomes measured repeatedly | All time points: 7% (5/69) Some time points: 48% (33/69) |
|
| Report amount of MD for secondary outcomes | For all: 9% (9/99)e For some: 18% (18/99) |
|
| Reasons for MD | Report reason for MDa | 71% (66/93)f |
| Report amount of MD because of death | 65% (60/93)f | |
| Report amount of MD because of illness or disease progression | 46% (43/93)f | |
| Minimizing MD | Report plans to minimize MD | 27% (29/108) |
| Risk of bias posed by MD | Report comparison of baseline characteristics of those with observed data | 6% (6/93)f |
| Report comparison of baseline characteristics of those with MD | 0% | |
| Justification of MD analytical approach | Report assumed mechanism of MDg | 3% (3/108) |
| Report criteria for MNAR (informative MD) | 1% (1/108) | |
| Report pattern of missingness | 0% | |
| Compare baseline characteristics of those with and without MD | 13% (12/93)e | |
| Statistical methods to handle MD | Report methods used to handle MD | 48% (45/93)e |
| Report methods used to handle truncated data because of death | 5% (3/60)h | |
| Report MD sensitivity analyses | 16% (15/93)f | |
| Report any changes to the planned MD analysis | 0% | |
| Impact of MD on the trial findings | Discuss impact of MD on the interpretation of findings | 46% (43/93)f |
Abbreviations: MD, missing data; MNAR, missing not at random.
a
The Consolidated Standards of Reporting Trials 2010 statement recommendation.
b
In non–crossover trials only.
c
For example, missing individual questions from a questionnaire, survey, or scale.
d
In 50 trials, the primary outcome was a scale summary.
e
In trials that measured secondary outcomes only.
f
About 15 trials reported no MD and therefore were excluded.
g
For example, missing completely at random, missing at random, or MNAR.
h
In trials that reported data was truncated due to death.